Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04314843
Title Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Kite, A Gilead Company
Indications

diffuse large B-cell lymphoma

B-cell lymphoma

primary mediastinal B-cell lymphoma

Therapies

axicabtagene ciloleucel + Lenzilumab

Cyclophosphamide + Fludarabine

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.